75 results about "Response to therapy" patented technology

Provided herein is the use of certain biomarkers, such as tryptophan and metabolites thereof for use in certain treatment methods. Suitable tryptophan metabolites that may serve as useful biomarkers include, for example, kynurenine (Kyn), kynurenic acid (KynA), and quinolinic acid. Such biomarkers may be used in identifying a subject who may benefit from treatment, predicting the responsiveness or monitoring the response of the subject to the treatment, or determining or adjusting the dosing or dosing regimen of the treatment to the subject.

Methods, devices and systems are provided to analyze the immunologic response of patients at various times before, during and / or after immunomodulating therapy, particularly treatment with specialized pulsed electric field energy. In some embodiments, such methods, devices and systems include a laboratory developed test that utilizes a patient tumor biopsy sample and a series of blood draws to determine whether the locoregional therapy (with or without additional systemic therapies, or systemic therapies-alone) was sufficient to facilitate an increase in tumor-specific antibody production. In some embodiments, the focus is on evaluation of baseline antibody levels, prior to any treatment, and changes in levels of antibodies to given antigens, especially in response to a given therapy treatment. In such embodiments, this antibody testing is performed prior to treatment. The treatment, such as delivery of specialized PEF energy to a target tissue, is then performed and antibody levels are checked at one or more later timepoints to detect changes in the presence of antibodies and therefore response to therapy.

Systems and methods are provided for creating report using the integrated prognostic signature indicating at least one of a diagnosis of the disease or a response of a subject to a treatment. The method may include receiving, by a system comprising a processor, a plurality of datasets from different modalities associated with a disease of a subject and determining, by the processor, a matrix of features for each of the plurality of data modalities. The method may also include integrating, by the processor, the matrix of features through a sequential, hierarchical structure to create an integrated prognostic signature for the subject, creating, by the processor, a report using the integrated prognostic signature indicating at least one of a diagnosis of the disease or a response of the subject to a treatment and displaying, by the system, the report.

The invention concerns methods for predicting changes in a tissue, comprising obtaining snap shot information on individual cells of at least one cell type in a section of a tissue biopsy, wherein the information comprises: (i) spatial localization, (ii) cell type and (iii) cell division state at a specific point in time; calculating cell division probabilities for each of said individual cells; determining cell population dynamics based on the cell division probabilities and predicting future changes in the tissue based thereon. Particularly, the method concerns predicting tissue dynamics in cancer biopsies relevant for prognosis, and assessment of response to therapy.

The present disclosure relates to methods for characterizing cancer testis antigen burden (“CTAB”), for predicting cancer survival outcomes using CTAB analysis, and for recommending and / or treating cancer using CTAB analysis. Particularly, aspects are directed to measuring expression of a panel of cancer testis antigen (CTA) gene markers in a tumor sample from a subject, determining a CTAB based on the measured expression of the CTA gene markers, classifying, by comparing to a reference CTAB score from the same cancer or tumor type, the CTAB score as a high-CTAB score or a low-CTAB score, and identifying the subject as responsive to a treatment wherein (i) the high-CTAB score is indicative of responsiveness to the treatment, or (ii) the low-CTAB score is indicative of responsiveness to the treatment.

An interferon (IFN)-anti-PD-L1 fusion protein, a pharmaceutical composition and a kit containing the same for treating tumors are disclosed. The fusion protein of the present invention can simultaneously target PD-L1 and IFN receptors, and the activation of IFN signals in a tumor microenvironment (TME) can enhance the PD-1 / PD-L1 therapy against tumors by inducing stronger T cell activation. The anti-PD-L1 antibody can be used to specifically deliver immunomodulatory molecules to tumor tissues, and the fusion protein results in the generation of multiple feedforward responses, which can increase the targeting effect, reduce the toxicity, and enhance the response to IFN therapy, thereby maximizing the anti-tumor effect.

The present invention relates to a method for in vitro method for diagnosing a cognitive impairment in a subject, or to in vitro method for monitoring the response to a therapy directed to improve the cognitive function in a subject suffering from cognitive impairment, comprising determining the expression levels of a gene specifically expressed in adipose tissue. The invention also discloses a kit to into practice the methods of the invention as well as a composition for use in the treatment of cognitive impairment by targeting the altered expression of this gene in adipose tissue.

The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.

A system, device, and method support receiving a data signal from one or more sensors associated with the system in response to therapy delivered to a patient. The system, device, and method support assigning a classification to one or more portions of a waveform associated with the data signal based on characteristic information associated with the one or more portions of the waveform. The system, device, and method support providing, based on the classification, one or more parameters associated with delivering the therapy.

The present disclosure provides methods and systems for screening or detecting a colorectal cancer or following colorectal disease progression that may be applied to cell-free nucleic acids such as cell-free DNA. The method may use detection of methylation signals within a single sequencing read in identified genomic regions as input features to train a machine learning model and generate a classifier useful for stratifying populations of individuals. The method may comprise extracting DNA from a cell-free sample obtained from a subject, converting the DNA for methylation sequencing, generating sequencing reads, and detecting colon proliferative cell disorder-associated signals in the sequencing information and training a machine learning model to provide a discriminator capable of distinguishing groups in a subject population such as healthy, cancer or distinguishing disease subtype or stage. The method may be used for, e.g., predicting, prognosticating, and / or monitoring response to treatment, tumor load, relapse, or colorectal cancer development.

Methods and systems for predicting a subject's response to a therapy by obtaining a first plurality of nucleic acid sequences for genomic DNA from a sample from the gut of a subject. Determine, from the nucleic acid sequences, a plurality of genomic abundance values for a plurality of gut bacteria. Apply a model to the plurality of genomic abundance values, thereby obtaining the prediction of a subject's response to a therapy as an output of the model.

A method for identifying a patient who will or is at risk of liver function decline in response to therapy with an antibiotic and / or antifungal agent, the method comprising measuring ethanol, one or more sugar fermentation products (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13 the concentration of ethanol, one or more sugar fermentation products, such as 2, 3-butanediol, and / or a direct ethanol biomarker, wherein the concentration of ethanol, one or more sugar fermentation products, such as 2, 3-butanediol, and / or a direct ethanol biomarker indicates that the patient will respond to therapy with an antibiotic and / or antifungal agent.

A method for monitoring treatment of a wound includes obtaining a photoacoustic ultrasound image of a wound on a patient. The photoacoustic ultrasound image is processed to extract information that is reflective of a rate of angiogenesis or oxygenation. A degree of wound healing is assessed based at least in part on the extracted information. The wound is treated based at least in part based on the assessed degree of wound healing. The treatment is monitored over time by obtaining and processing additional photoacoustic ultrasound images at subsequent times.

Disclosed herein are devices, compositions, methods, and systems for identifying mammalian cells, especially erythrocytes, with enhanced characteristics, such as hemolysis, stress tolerance, oxygen capacity, and energy metabolism. In some embodiments, the devices, compositions, methods, and systems may be useful in identifying a subject for donating erythrocytes, with enhanced stress resistance, with enhanced physical performance such as oxygen consumption, and strenuous or prolonged physical activities, hemorrhage, or resistance to high altitude hypoxia. Subjects may also be identified for donating cells for use in manufacture of next-generation ex vivo farmed RBCs with optimal storage and resuscitation performances. The disclosed devices, compositions, methods and systems are also useful in the bioengineering of red blood cells and red blood cell precursor ex vivo from hematopoietic stem cells or induced pluripotent stem cells, as well as ithe prediction of cancer progression, severity and responses to therapies targeting glycolysis.

The present invention is directed to methods for detecting a colon cancer, methods for determining whether a colon cancer is stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a colon cancer to a therapy.

Disclosed are methods and agents for predicting response to therapy, immune status and / or disease progression. More particularly, disclosed are methods, agents and kits for analyzing cellular distribution of PD-L2, including its nuclear localization, for stratifying a patient as a likely responder or non-responder to a therapy, for managing treatment of a patient with a therapy, for monitoring a disease in a patient following treatment with a therapy, for determining the status of a disease and / or for determining the immune status of a patient.

The present invention relates to methods of determining the presence or absence of certain cancers in a human individual, as well as to related methods to determine the response to therapy against certain cancers in a human individual, in particular ovarian cancer in a woman. Such methods are based on the detection—from (eg cell-free) DNA of said human individual—of one or more methylated (or un-methylated) CpGs being associated with differentially methylated regions (DMRs) of the present invention; such as methylation (or un-methylation) at one or more or all of certain CpGs being associated with such DMRs. Accordingly, such methods have diagnostic, prognostic and / or predictive utility for detecting or managing certain cancers in women or men, in particular ovarian cancer in women. The present invention further relates to nucleic acids comprising certain sequences that may be detected during the method, or nucleic acids (such as probes and / or primers) that are useful to detect such sequences, as wells as compositions, kits, computer program products and other aspects that are useful for or related to the practice or application of such methods.

To provide use of molecular profiling for deriving recommendation of individualized treatment for a patient.SOLUTION: Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.SELECTED DRAWING: Figure 1C

In a first aspect, the present invention relates to a method of determining whether a subject who has been diagnosed with melanoma is amenable to a treatment with immune checkpoint inhibitor(s) ICI(s) wherein the method comprises determination of the level and / or amount of IL-17 in a biological sample obtained from the subject and drawing a conclusion as to the amenability of said subject to a treatment with ICI(s) from the level and / or amount of IL-17 determined in said biological sample. Moreover, the present invention relates to a method for determining the therapy regimen of a subject who has been diagnosed with melanoma whereby the therapy comprise a treatment with ICI(s). Said method includes the measurement of the level and / or amount of IL-17 in a biological sample obtained from the subject and concluding whether the therapy regimen of said subject is amenable to a treatment with ICI(s) from the determined level or amount of IL- 17. Moreover, a method for determining responsiveness of the subject has been diagnosed with melanoma to a treatment with ICI(s) is disclosed. In a further aspect, the present invention relates to the use of IL-17 for predicting response to ICI therapy and / or for stratification of ICI in a subject who has been diagnosed with melanoma, in particular, metastatic melanoma. Moreover, the present invention relates to a pharmaceutical composition comprising a combination of IL-17 with at least one the ICI, in particular, being selected from anti-PD1 ICI and anti-CTLA-4 ICI.

In certain example embodiments, an air delivery system includes a controllable flow generator operable to generate a supply of pressurized breathable gas to be provided to a patient for treatment and a pulse oximeter. In certain example embodiments, the pulse oximeter is configured to determine, for example, a measure of patient effort during a treatment period and provide a patient effort signal for input to control operation of the flow generator. Oximeter plethysmogram data may be used, for example, to determine estimated breath phase; sleep structure information; autonomic improvement in response to therapy; information relating to relative breathing effort, breathing frequency, and / or breathing phase; vasoconstrictive response, etc. Such data may be useful in diagnostic systems.

tFUS delivery and tracking systems and methods assess target location accuracy and therapy efficacy by measuring the specific and predicted downstream effects in individualistic responses to tFUS waveforms. The downstream effects include physiological, stress, mood, movement, attention measurements, subjective reports, task-based performance, etc. The measurements are performed before, during, and between tFUS sessions intermixed with optional control periods or sessions. In an embodiment, when a target brain region does not offer any immediate readouts but is surrounded by regions that may, these latter regions can be used instead for triangulation or waveform optimization. Individual and group tracking methods help identify useful measurement modalities and the expected direction and magnitude of change in response to therapy. A method that enables individualized functional targeting in a non-clinical setting by optimizing cost and complexity is described.

Provided are methods and systems for detecting a polymorphism in one or more glucagon-like protein-1 receptor (GLP-1R) related markers, and optionally detecting one or more metabolic markers or neural markers, in a subject. Also provided are methods and systems for predicting a risk for developing GLP-1R associated condition or a response to a GLP-1R agonist therapy in a subject by detecting a polymorphism in one or more GLP-1R related markers, and optionally detecting one or more metabolic markers or neural markers. The methods and systems can be used for selecting a treatment regimen, monitoring a response to the treatment, or adjusting the treatment regimen in the subject.

Methods, devices and systems are provided to analyze the immunologic response of patients at various times before, during and / or after immunomodulating therapy, particularly treatment with specialized pulsed electric field energy, in some embodiments, such methods, devices and systems include a laboratory developed test that utilizes a patient tumor biopsy sample and a series of blood draws to determine whether the locoregional therapy (with or without additional systemic therapies, or systemic therapies-alone) was sufficient to facilitate an increase in tumor-specific antibody production. In some embodiments, the focus is on evaluation of baseline antibody levels, prior to any treatment, and changes in levels of antibodies to given antigens, especially in response to a given therapy treatment. The treatment, such as delivery of specialized FEF energy to a target tissue, is then performed and antibody levels are checked at one or more later timepoints to detect changes in the presence of antibodies and therefore response to therapy.

Methods for quantifying DNA methylation that may be utilized for screening for diseases (e.g., cancer), diagnosing diseases (e.g., cancer type), monitoring progression of a disease, and monitoring response to a therapeutic treatment.

Disclosed herein are systems and methods of generating skin disease treatment classes. Also described herein are methods for using the methods described herein for assessing potential response to therapies for treating skin diseases or skin conditions.

The invention relates to methods of predicting a patient's responsiveness to treatment (e.g., vedolizumab treatment) for inflammatory bowel disease (IBD).

The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.

The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.

This invention discloses a method and system for predicting a subject's response to a therapy by: obtaining a first plurality of nucleic acid sequences targeting genomic DNA from a sample of the subject's gut; determining multiple genomic abundance values ​​for various gut bacteria from the nucleic acid sequences; and applying a model to the plurality of genomic abundance values ​​to obtain a prediction of the subject's response to the therapy as the output of the model.

Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.